Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Want to see AU:ACL full AI Analyst Report?
ACL Stock Chart & Stats
AU$2.09
AU$0.08(2.29%)
At close: 4:00 PM EST
AU$2.09
AU$0.08(2.29%)
Day’s Range― - ―
52-Week RangeAU$1.87 - AU$3.24
Previous CloseN/A
Volume421.17K
Average Volume (3M)867.30K
Market Cap
AU$358.45M
Enterprise ValueAU$789.63M
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)23.9
Beta0.94
Next Earnings
Aug 26, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)0.07
Shares Outstanding187,672,410
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.33Price Target Upside11.24% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.16
Revenue Forecast (FY)AU$736.59M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent improvement in free cash flow and high cash conversion ratios show durable operating cash generation. This provides flexibility to fund working capital, capex, dividends or debt reduction without relying on equity markets, supporting resilience across economic cycles.
Improving Gross MarginA materially higher gross margin indicates sustainable cost improvements or better mix toward higher-value tests. Improved unit economics supports margin resilience even if volumes soften, enabling reinvestment in labs or pricing flexibility against reimbursement pressures.
High Return On EquityROE near 19% signals the business can generate solid returns on invested equity, reflecting operational efficiency and profitable service contracts. Over 2-6 months, strong ROE supports capital allocation credibility and shareholder distributions if cash generation persists.
Bears Say
High LeverageSignificant leverage raises refinancing and interest rate risk, constraining strategic flexibility. In a diagnostics business with payment timing and reimbursement uncertainty, high debt levels make the firm more vulnerable to volume shocks or adverse contract renewals over the medium term.
Low Net MarginA low net margin despite improving gross margins suggests elevated operating or financing costs that limit cash available for reinvestment. Persistently thin net profitability reduces the buffer against reimbursement cuts and makes funding growth or debt servicing more challenging.
Modest Revenue GrowthVery limited top-line growth points to constrained market expansion or pricing pressure in core pathology markets. Over months, slow revenue momentum reduces scale benefits, limits margin expansion opportunities, and heightens dependency on cost cuts or acquisitions for earnings improvement.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.87 and its highest was AU$3.24 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$358.45M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 117 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.09 which represents an annual dividend yield of 4.6%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.1.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 187,672,410 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.33 (11.24% Upside)
AU$2.33 (11.24% Upside)
Insider Transactions
Bought Shares
Worth AU$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.33
▲(11.24% Upside)
Technical Analysis
Options Prices
Currently, No data available
---